{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:59:41Z","timestamp":1792403981421,"version":"4.4.0"},"reference-count":49,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1536\/ihj.15-346","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T22:06:06Z","timestamp":1457647566000},"page":"134-139","source":"Crossref","is-referenced-by-count":146,"title":["Inflammatory Biomarkers and Atherosclerosis"],"prefix":"10.1536","volume":"57","author":[{"given":"Takeshi","family":"Soeki","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Sata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180: 1332-9.","DOI":"10.1126\/science.180.4093.1332"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Williams KJ, Tabes I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-61. (Review)","DOI":"10.1161\/01.ATV.15.5.551"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-25. (Review)","DOI":"10.1038\/nature10146"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Koenig W, L\u00f6wel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109: 1349-53.","DOI":"10.1161\/01.CIR.0000120707.98922.E3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Goldstein JA, Chandra HR, O\u2019Neill WW. Relation of number of complex coronary lesions to serum C-reactive protein levels and major adverse cardiovascular events at one year. Am J Cardiol 2005; 96: 56-60.","DOI":"10.1016\/j.amjcard.2005.02.044"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.","DOI":"10.1161\/01.CIR.101.15.1767"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Cesari M, Penninx BW, Newman AB, <i>et al<\/i>. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-22.","DOI":"10.1161\/01.CIR.0000097109.90783.FC"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Weber C, Schober A, Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1997-2008. (Review)","DOI":"10.1161\/01.ATV.0000142812.03840.6f"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Niki T, Soeki T, Yamaguchi K, <i>et al<\/i>. Elevated concentration of interferon-inducible protein of 10 kD (IP-10) is associated with coronary atherosclerosis. Int Heart J 2015; 56: 269-72.","DOI":"10.1536\/ihj.14-300"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Virella G, Koskinen S, Krings G, Onorato JM, Thorpe SR, Lopes-Virella M. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol 2000; 95: 135-44.","DOI":"10.1006\/clim.2000.4857"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Matsuo Y, Kubo T, Okumoto Y, <i>et al<\/i>. Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease. Eur Heart J Cardiovasc Imaging 2013; 14: 43-50.","DOI":"10.1093\/ehjci\/jes094"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm 2013; 2013: 152786. (Review)","DOI":"10.1155\/2013\/152786"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hayashida K, Kume N, Murase T, <i>et al<\/i>. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 2005; 112: 812-8.","DOI":"10.1161\/CIRCULATIONAHA.104.468397"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am J Hypertens 2001; 14: 44S-54S. (Review)","DOI":"10.1016\/S0895-7061(01)02069-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. G\u00fcray U, Erbay AR, G\u00fcray Y, <i>et al<\/i>. Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis. Int J Cardiol 2004; 96: 235-40.","DOI":"10.1016\/j.ijcard.2003.07.014"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N. Increased soluble platelet\/endothelial cell adhesion molecule-1 in the early stages of acute coronary syndromes. Int J Cardiol 2003; 90: 261-8.","DOI":"10.1016\/S0167-5273(02)00564-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013-20. (Review)","DOI":"10.1161\/01.CIR.94.8.2013"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000; 83: 361-6. (Review)","DOI":"10.1136\/heart.83.3.361"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Narula J, Finn AV, Demaria AN. Picking plaques that pop. J Am Coll Cardiol 2005; 45: 1970-3.","DOI":"10.1016\/j.jacc.2005.03.034"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007; 17: 253-8. (Review)","DOI":"10.1016\/j.tcm.2007.09.001"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Blankenberg S, Rupprecht HJ, Poirier O, <i>et al<\/i>; AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-85.","DOI":"10.1161\/01.CIR.0000058700.41738.12"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 2000; 20: 1716-23. (Review)","DOI":"10.1161\/01.ATV.20.7.1716"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tavora FR, Ripple M, Li L, Burke AP. Monocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques. BMC Cardiovasc Disord 2009; 9: 27.","DOI":"10.1186\/1471-2261-9-27"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Meuwese MC, Stroes ES, Hazen SL, <i>et al<\/i>. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007; 50: 159-65.","DOI":"10.1016\/j.jacc.2007.03.033"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Brennan ML, Penn MS, Van Lente F, <i>et al<\/i>. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595-604.","DOI":"10.1056\/NEJMoa035003"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kolodgie FD, Burke AP, Skorija KS, <i>et al<\/i>. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2523-9.","DOI":"10.1161\/01.ATV.0000244681.72738.bc"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, <i>et al<\/i>. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375: 1536-44.","DOI":"10.1016\/S0140-6736(10)60319-4"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-66. (Review)","DOI":"10.1146\/annurev.immunol.23.021704.115756"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Bonacina F, Baragetti A, Catapano AL, Norata GD. Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases. Mediators Inflamm 2013; 2013: 725102. (Review)","DOI":"10.1155\/2013\/725102"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Inoue K, Sugiyama A, Reid PC, <i>et al<\/i>. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007; 27: 161-7.","DOI":"10.1161\/01.ATV.0000252126.48375.d5"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Soeki T, Niki T, Kusunose K, <i>et al<\/i>. Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. J Cardiol 2011; 58: 151-7.","DOI":"10.1016\/j.jjcc.2011.04.005"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Nebuloni M, Pasqualini F, Zerbi P, <i>et al<\/i>. PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis. Cardiovasc Pathol 2011; 20: e27-35.","DOI":"10.1016\/j.carpath.2010.02.005"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Latini R, Maggioni AP, Peri G, <i>et al<\/i>; Lipid Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349-54.","DOI":"10.1161\/01.CIR.0000145167.30987.2E"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Dagna L, Salvo F, Tiraboschi M, <i>et al<\/i>. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011; 155: 425-33.","DOI":"10.7326\/0003-4819-155-7-201110040-00005"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Latini R, Gullestad L, Masson S, <i>et al<\/i>; Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail 2012; 14: 992-9.","DOI":"10.1093\/eurjhf\/hfs092"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007; 117: 2369-76. (Review)","DOI":"10.1172\/JCI33099"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Mitchell PS, Parkin RK, Kroh EM, <i>et al<\/i>. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-8.","DOI":"10.1073\/pnas.0804549105"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012; 110: 483-95. (Review)","DOI":"10.1161\/CIRCRESAHA.111.247452"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Takeishi Y. Biomarkers in heart failure. Int Heart J 2014; 55: 474-81. (Review)","DOI":"10.1536\/ihj.14-267"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S, Zeiher AM. Transcoronary concentration gradients of circulating microRNAs. Circulation 2011; 124: 1936-44.","DOI":"10.1161\/CIRCULATIONAHA.111.037572"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008; 105: 1516-21.","DOI":"10.1073\/pnas.0707493105"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Zernecke A, Bidzhekov K, Noels H, <i>et al<\/i>. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2: ra81.","DOI":"10.1126\/scisignal.2000610"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Soeki T, Yamaguchi K, Niki T, <i>et al<\/i>. Plasma microRNA-100 is associated with coronary plaque vulnerability. Circ J 2015; 79: 413-8.","DOI":"10.1253\/circj.CJ-14-0958"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Kumada M, Kihara S, Sumitsuji S, <i>et al<\/i>; Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-9.","DOI":"10.1161\/01.ATV.0000048856.22331.50"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-7.","DOI":"10.1001\/jama.291.14.1730"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Hirata Y, Tabata M, Kurobe H, <i>et al<\/i>. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol 2011; 58: 248-55.","DOI":"10.1016\/j.jacc.2011.01.048"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Kim SH, Chung JH, Kwon BJ, Song SW, Choi WS. The associations of epicardial adipose tissue with coronary artery disease and coronary atherosclerosis. Int Heart J 2014; 55: 197-203.","DOI":"10.1536\/ihj.13-303"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, <i>et al<\/i>. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379: 1205-13.","DOI":"10.1016\/S0140-6736(11)61931-4"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379: 1214-24.","DOI":"10.1016\/S0140-6736(12)60110-X"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/57\/2\/57_15-346\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T12:13:04Z","timestamp":1567685584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/57\/2\/57_15-346\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.15-346","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}